Emerging Health Care Issues: Follow-On Biologic Drug Competition
http://www.ftc.gov/os/2009/06/P083901biologicsreport.pdf
Examines whether to create a legal process, like the Hatch-Waxman Act, to encourage competiton between follow-on biologic drugs and expensive pioneer biologic drugs to bring about reduced prices, and whether such a process would be comparable to competition between brand name and generic chemicially synthesized drug products. From the Federal Trade Commission.
Comments
Comments are not allowed for this entry.
